A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer
The DOI matches its OpenAlex record.
Abstract
3514 Background: Gefitinib (ZD1839, Iressa) is an inhibitor of epidermal growth factor receptor-1 and has been shown to produce growth inhibition and shrinkage in human tumors. Here we report the preliminary results of a trial to evaluate the efficacy and toxicity of Gefitinib (I) with FOLFOX-4 in patients (pts) with advanced colorectal cancer. Methods: Each cycle consisted of 14 days. Cycle 1 consisted of FOLFOX-4 while cycle 2 and subsequent cycles consisted of FOLFOX-4 with gefitinib at 500 mg PO qd. Pts were stratified by prior therapy for metastatic disease; Group A with no prior therapy and Group B with prior therapy Results: 56 pts have been enrolled (Group A: N=32; Group B: N=24) to date. Median age 54 years (range, 37–79) and median ECOG PS 0 (range 0–1). No patient had prior oxaliplatin. 359 cycles have been administered to date. All pts were assessable for toxicity and 49 were assessable for response. Two pts withdrew prior to completing 4 cycles due to unacceptable toxicity. Grade 3/4 toxicities included neutropenia (53%), diarrhea (49%), nausea (28%), and vomiting (21%). There was one treatment-related death (E. coli sepsis). In Group A, 21 of 27 pts (78%) achieved a partial response (PR). Nine patients in Group A went on to have liver metastases resected; only four of whom were deemed to have resectable disease at study entry. In Group B, 8 of 22 pts (36%) achieved PR. 18 of 22 Group B pts (82%) had received both Irinotecan and 5-FU. Conclusions: Gefitinib with FOLFOX 4 represents an active regimen with response rates that are thus far encouraging compared with previously reported results using FOLFOX alone. Accrual continues to date. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca; Bristol-Myers Squibb; Genentech; Sanofi-Synthelabo Roche AstraZeneca
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 632
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Metadata
- Authors
- Fisher, G. A., Kuo, T., Cho-Phan, C. D., Halsey, J., Jambalos, C. N., Schwartz, E., Rouse, R. V., Advani, R. H., & Wakelee, H. A.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14_suppl
- Pages
- 3514-3514
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2242958373
- Cited by
- 89
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2004.22.14_suppl.3514
- The paper
- Fisher, G. A., Kuo, T., Cho-Phan, C. D., Halsey, J., Jambalos, C. N., Schwartz, E., Rouse, R. V., Advani, R. H., & Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.22.14_suppl.3514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.